Plain-English translation of NCT07013474 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new antiviral medicine called to treat COVID-19 in people with severely weakened immune systems. Researchers want to see if this medication works better alone or when combined with an existing COVID-19 treatment called . All participants will receive active treatment — the study will compare how well the medication works in different combinations.
People with severely weakened immune systems struggle to fight COVID-19 on their own and are at risk for persistent infections and serious illness. Current treatments may not be enough for this population, so doctors are testing whether this medication or combinations of treatments could help them recover better.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive one of three treatment options: the new medication alone, the new medication plus , or alone. You will take pills by mouth twice daily and receive IV infusions, with placebos used so you won't know which treatment you're getting. Over 24 weeks, you'll attend about 10 study visits for blood work, nasal swabs (some done at home), and questionnaires.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States